Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: results from the SAL-MODULE phase I study

We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three...

Full description

Bibliographic Details

Main Authors:	Röllig, Christoph (Author) , Schliemann, Christoph (Author) , Ruhnke, Leo (Author) , Fransecky, Lars (Author) , Heydrich, Björn-Niklas (Author) , Hanoun, Maher (Author) , Noppeney, Richard (Author) , Schäfer-Eckart, Kerstin (Author) , Wendelin, Knut (Author) , Mikesch, Jan-Henrik (Author) , Middeke, Jan Moritz (Author) , Reimann, Manja (Author) , Fiebig, Frank (Author) , Zukunft, Sven (Author) , Wermke, Martin (Author) , Serve, Hubert (Author) , Platzbecker, Uwe (Author) , Müller-Tidow, Carsten (Author) , Baldus, Claudia D. (Author) , Bornhäuser, Martin (Author)
Format:	Article (Journal)
Language:	English
Published:	June 2024
In:	British journal of haematology Year: 2024, Volume: 204, Issue: 6, Pages: 2254-2258
ISSN:	1365-2141
DOI:	10.1111/bjh.19436
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/bjh.19436 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.19436
Author Notes:	Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Kerstin Schäfer-Eckart, Knut Wendelin, Jan-Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, Frank Fiebig, Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, Martin Bornhäuser